People · Operator
Named in public records as an officer, director or promoter · active 2016–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Abpro Corp | — | Biotechnology | Series B | $42.4M | $37.5M | 2016 |
Ian Chan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ian Chan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| Thomas S. Weng | 1 | 3 |
| Adam S. Mostafa | 1 | 2 |
| Thomas Weng | 1 | 2 |
| Robert J. Langer | 1 | 2 |
| Mark J. Tang | 1 | 1 |
| Kevin Comerford | 1 | 1 |
| Eugene Chan | 1 | 1 |
| Mark Tang | 1 | 1 |
| Miles Suk | 1 | 1 |
| Miles J. Suk | 1 | 1 |
| Feng S. Ye | 1 | 1 |
| Benjamin Ha | 1 | 1 |
| Shengxin Qin | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.